Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary (8) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Summaries of opinion (22) Apply Summaries of opinion filter Withdrawn applications (52) Apply Withdrawn applications filter Orphan designations (236) Apply Orphan designations filter Referrals (19) Apply Referrals filter Direct healthcare professional communication (28) Apply Direct healthcare professional communication filter

Product number

Patient safety

Yes (2) Apply Yes filter

Authorisation status

Authorised (404) Apply Authorised filter Refused (15) Apply Refused filter Withdrawn (40) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (19) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (167) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (2) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter W: decision granting a waiver in all age groups for all conditions or indications (42) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (32) Apply Yes filter

Compliance procedure number

Medicine type

Accelerated assessment Remove Accelerated assessment filter Additional monitoring Remove Additional monitoring filter Orphan medicine Remove Orphan medicine filter Biosimilar (86) Apply Biosimilar filter Conditional approval (76) Apply Conditional approval filter Exceptional circumstances (49) Apply Exceptional circumstances filter Generic (269) Apply Generic filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

691 results

Remove all filtersRemove all filters

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter

Categories Human Remove Human filter

Medicine type Accelerated assessment Remove Accelerated assessment filter Additional monitoring Remove Additional monitoring filter Orphan medicine Remove Orphan medicine filter

Sort by

List item

Human medicine European public assessment report (EPAR): Rinvoq (updated)

upadacitinib, Arthritis, Rheumatoid
Date of authorisation: 16/12/2019, , Revision: 9, Authorised, Last updated: 20/05/2022
List item

Human medicine European public assessment report (EPAR): Breyanzi (updated)

CD19-directed genetically modified autologous cell-based product consisting of purified CD8+ T-cells (CD8+ cells), CD19-directed genetically modified autologous cell-based product consisting of purified CD4+ T cells (CD4+ cells), Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Mediastinal Neoplasms
Date of authorisation: 04/04/2022, , Authorised, Last updated: 20/05/2022
List item

Human medicine European public assessment report (EPAR): Cinryze (updated)

C1 inhibitor (human), Angioedemas, Hereditary
Date of authorisation: 15/06/2011, , Revision: 22, Authorised, Last updated: 20/05/2022
List item

Human medicine European public assessment report (EPAR): Xospata (updated)

gilteritinib fumarate, Leukemia, Myeloid, Acute
Date of authorisation: 24/10/2019, , , Revision: 3, Authorised, Last updated: 20/05/2022
List item

Human medicine European public assessment report (EPAR): Elaprase (updated)

idursulfase, Mucopolysaccharidosis II
Date of authorisation: 08/01/2007, , , Revision: 22, Authorised, Last updated: 20/05/2022
List item

Human medicine European public assessment report (EPAR): MenQuadfi (updated)

Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid, Meningitis, Meningococcal
Date of authorisation: 18/11/2020, , Revision: 6, Authorised, Last updated: 19/05/2022
List item

Human medicine European public assessment report (EPAR): Kymriah (updated)

tisagenlecleucel, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 22/08/2018, , , Revision: 11, Authorised, Last updated: 19/05/2022
List item

Human medicine European public assessment report (EPAR): Mysimba (updated)

bupropion hydrochloride, naltrexone hydrochloride, Obesity; Overweight
Date of authorisation: 26/03/2015, , Revision: 21, Authorised, Last updated: 19/05/2022
List item

Human medicine European public assessment report (EPAR): Uplizna (updated)

Inebilizumab, Neuromyelitis Optica
Date of authorisation: 25/04/2022, , Authorised, Last updated: 19/05/2022
List item

Human medicine European public assessment report (EPAR): Ondexxya (updated)

andexanet alfa, Drug-Related Side Effects and Adverse Reactions
Date of authorisation: 26/04/2019, , , Revision: 11, Authorised, Last updated: 18/05/2022
List item

Human medicine European public assessment report (EPAR): PreHevbri (updated)

hepatitis B surface antigen, Hepatitis B
Date of authorisation: 25/04/2022, , Authorised, Last updated: 18/05/2022
List item

Human medicine European public assessment report (EPAR): Ayvakyt (updated)

avapritinib, Gastrointestinal Stromal Tumors
Date of authorisation: 24/09/2020, , , Revision: 4, Authorised, Last updated: 18/05/2022
List item

Human medicine European public assessment report (EPAR): Padcev (updated)

Enfortumab vedotin, Carcinoma, Transitional Cell; Urologic Neoplasms
Date of authorisation: 13/04/2022, , Authorised, Last updated: 18/05/2022
List item

Human medicine European public assessment report (EPAR): Alunbrig (updated)

brigatinib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 22/11/2018, , Revision: 8, Authorised, Last updated: 18/05/2022
List item

Human medicine European public assessment report (EPAR): Cometriq (updated)

cabozantinib, Thyroid Neoplasms
Date of authorisation: 21/03/2014, , Revision: 24, Authorised, Last updated: 18/05/2022
List item

Human medicine European public assessment report (EPAR): Keytruda (updated)

Pembrolizumab, Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Urologic Neoplasms; Endometrial Neoplasms
Date of authorisation: 17/07/2015, , Revision: 44, Authorised, Last updated: 17/05/2022
List item

Human medicine European public assessment report (EPAR): Bimzelx (updated)

bimekizumab, Psoriasis
Date of authorisation: 20/08/2021, , Revision: 1, Authorised, Last updated: 17/05/2022
List item

Human medicine European public assessment report (EPAR): Tobi Podhaler (updated)

Tobramycin, Cystic Fibrosis; Respiratory Tract Infections
Date of authorisation: 20/07/2011, , Revision: 19, Authorised, Last updated: 13/05/2022
List item

Human medicine European public assessment report (EPAR): Dupixent (updated)

dupilumab, Dermatitis, Atopic
Date of authorisation: 26/09/2017, , Revision: 15, Authorised, Last updated: 13/05/2022
List item

Human medicine European public assessment report (EPAR): Ilumetri (updated)

tildrakizumab, Psoriasis
Date of authorisation: 17/09/2018, , Revision: 5, Authorised, Last updated: 13/05/2022
List item

Human medicine European public assessment report (EPAR): Zytiga (updated)

abiraterone acetate, Prostatic Neoplasms
Date of authorisation: 05/09/2011, , Revision: 24, Authorised, Last updated: 13/05/2022
List item

Human medicine European public assessment report (EPAR): Kalydeco (updated)

ivacaftor, Cystic Fibrosis
Date of authorisation: 23/07/2012, , , Revision: 33, Authorised, Last updated: 12/05/2022
List item

Human medicine European public assessment report (EPAR): Imraldi (updated)

adalimumab, Spondylitis, Ankylosing; Arthritis, Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Hidradenitis Suppurativa; Arthritis
Date of authorisation: 24/08/2017, , , Revision: 16, Authorised, Last updated: 12/05/2022
List item

Human medicine European public assessment report (EPAR): SomaKit TOC (updated)

edotreotide, Neuroendocrine Tumors; Radionuclide Imaging
Date of authorisation: 08/12/2016, , Revision: 11, Authorised, Last updated: 12/05/2022
List item

Human medicine European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna) (updated)

CX-024414 (single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2), COVID-19 virus infection
Date of authorisation: 06/01/2021, , , , Revision: 22, Authorised, Last updated: 12/05/2022